Here are five quick facts:
1. AmSurg’s target price could deviate by a maximum of $7.7 from the forecast price.
2. Analysts predict the target price could reach a high of $95 and a low of $70.
3. Zacks analysts gave the company a “strong buy” rating for the short term.
4. In the last three-month period, AmSurg shares have dropped nearly 4.8 percent.
5. The shares posted positive gains of 2.51 percent in the last four weeks.
More articles on surgery centers:
Medical Facilities reports Q3 results — 5 highlights
Clarus Eye Centre in Washington expands to new facility: 5 key notes
NC surgery center asks to transfer operating rooms: 5 key notes
